These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24131622)

  • 1. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
    Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
    Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
    Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
    Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
    Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
    PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
    Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
    Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
    Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
    BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
    Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
    Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
    Sridharan S; Basu A
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
    Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
    Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
    Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
    Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
    Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
    Lehn S; Tobin NP; Sims AH; Stål O; Jirström K; Axelson H; Landberg G
    BMC Cancer; 2014 Feb; 14():119. PubMed ID: 24559095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal expression of p-AMPKa and p-S6 is strongly associated with the prognosis of gastric cancer.
    Zheng Z; Zheng Y; Zhang M; Wang J; Yu G; Fang W
    Tumour Biol; 2016 Apr; 37(4):4803-11. PubMed ID: 26520441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
    Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
    Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.